Metacrine is a privately held biotech company founded in 2015 on technology licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Metacrine or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
EQUITYZEN and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.